Disease Domain | Count |
---|---|
Neoplasms | 2 |
Endocrinology and Metabolic Disease | 1 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Diagnostic radiopharmaceuticals | 1 |
Biosimilar | 1 |
Colony-stimulating factors | 1 |
Recombinant protein | 1 |
Target |
Mechanism FAP antagonists |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseEarly Phase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism USP47 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism NLRP3 inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date20 Feb 2025 |
Sponsor / Collaborator |
Start Date01 Oct 2024 |
Sponsor / Collaborator |
Start Date01 Jun 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
18F-AlF-FAPi-04 ( FAP ) | Solid tumor More | Phase 1 Clinical |
Pegfilgrastim biosimilar(Affliated Hospital Of North Sichuan Medical College) ( CSF-3R ) | Neutropenia More | Clinical |
P22077 ( USP47 x USP7 ) | Pulmonary Disease, Chronic Obstructive More | Preclinical |
Tetramethylpyrazine ( NLRP3 ) | Myocardial Reperfusion Injury More | Preclinical |
CN117205302 ( Collagen ) | Nutritional and Metabolic Diseases More | Discovery |